772 Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?

Authors :: D. Schallier
Linda Dhondt
Peter Schatteman
J. Van Haverbeke
S. Rottey
D. Schrijvers
Els Everaert
F. Van Aelst
Jolanda Verheezen
Joanna Vermeij
Thierry Gil
Marylene Clausse
C. Van Praet
J. C. Goeminne
Patrick Werbrouck
Jeroen Mebis
Nicolaas Lumen
Bertrand Filleul
Wim Demey
F. Van Hende
J. Van Erps
W. Wynendaele
Gino Pelgrims
Marika Rasschaert
J-P. Machiels
Source :: European Urology Supplements. 15:e772-e772a
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Urology
Abiraterone acetate
Castration resistant
medicine.disease
chemistry.chemical_compound
Prostate cancer
chemistry
Docetaxel
Internal medicine
medicine
Overall survival
business
medicine.drug

Full Text Access

Tools